Nebenwirkungen · Cabazitaxel Accord
Cabazitaxel Accord 20 mg/ml concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 11
HOS-144896 · Präparat HOS-099284
Neutropenia, and associated clinical events The use of G-CSF has been shown to limit the incidence and severity of neutropenia (see sections 4.2 and 4.4). Incidence of grade ≥3 neutropenia based on laboratory data varied depending on use of G-CSF from 44.7% to 76.7%, with the lowest incidence reported when G-CSF prophylaxis was used. Similarly, the incidence of grade ≥ 3 febrile neutropenia ranged from 3.2% to 8.6%. Neutropenic complications (including febrile neutropenia, neutropenic infection/sepsis and neutropenic colitis) which in some cases resulted in a fatal outcome, were reported in 4.0% of the patients when primary G-CSF prophylaxis was used, and in 12.8% of the patients otherwise.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-07T12:43:00Z · SHA-256 e94990ee8411fa544039e204cf256f3e804b1eb52641ffca9b2a77499ea7c894 · Passage 4df64a682c575de8601ef2378769a1643c5c45fc284ee67d8be924d70eeb93e0 · Zeichen 13884–14583 im Abschnitt